(Q43982169)

28 November 2017

title

Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer (English)

1 reference

28 November 2017

1 reference

M Lees

1

1 reference

28 November 2017

M Aristides

2

1 reference

28 November 2017

N Maniadakis

3

1 reference

28 November 2017

J McKendrick

4

1 reference

28 November 2017

N Botwood

5

1 reference

28 November 2017

D Stephenson

6

1 reference

28 November 2017

publication date

1 January 2002

1 reference

28 November 2017

1 reference

28 November 2017

volume

20

1 reference

28 November 2017

issue

5

1 reference

28 November 2017

page(s)

325-337

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-200220050-00004

28 November 2017

exact match

0 references

cites work

Phase III trial of cisplatin/gemcitabine with or without vinorelbine or paclitaxel in advanced non-small cell lung cancer

1 reference

12 December 2020

Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer

1 reference

12 December 2020

Epidemiology of lung cancer

1 reference

12 December 2020

Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: an estimate using the Population Health Model lung cancer module.

1 reference

12 December 2020

Gemcitabine--a new agent in the treatment of non-small cell lung cancer. A commentary.

1 reference

12 December 2020

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer

1 reference

12 December 2020

Results of an independent oncology review board of pivotal clinical trials of gemcitabine in non-small cell lung cancer

1 reference

12 December 2020

Advanced non-small cell lung cancer in the elderly: effective and well tolerated weekly gemcitabine and cisplatin regimen. A pilot study.

1 reference

12 December 2020

Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: a phase III randomized study. Preliminary results. Hellenic Cooperative Oncology Group

1 reference

12 December 2020

The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer

1 reference

12 December 2020

Economic evaluation of gemcitabine single agent therapy compared with standard treatment in stage IIIB and IV non-small cell lung cancer

1 reference

12 December 2020

Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project

1 reference

12 December 2020

Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer

1 reference

12 December 2020

Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study

1 reference

12 December 2020

The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: an Italian perspective.

1 reference

12 December 2020

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

12 December 2020

Interim results of a phase III trial. Paclitaxel/carboplatin vs paclitaxel/gemcitabine in advanced non-small-cell lung cancer.

1 reference

12 December 2020

1 reference

12 December 2020

Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis

1 reference

12 December 2020

Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer

1 reference

12 December 2020

Gemcitabine in non-small cell lung cancer (NSCLC).

1 reference

12 December 2020

Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer

1 reference

12 December 2020

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group

1 reference

12 December 2020

Chemotherapy versus palliative care in non-small cell lung cancer

1 reference

12 December 2020

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer

1 reference

12 December 2020

The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer

1 reference

12 December 2020

Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Onc

1 reference

12 December 2020

Gemcitabine: clinical and economic impact in inoperable non-small cell lung cancer

1 reference

12 December 2020

10.2165/00019053-200220050-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

28 November 2017

1020531211

0 references

1 reference